Alphatec Holdings Revenue 2011-2026 | ATEC

Company revenue is the total amount of money received from the sale of goods or services over a certain period of time. It is one of the key indicators of a company's financial condition and success.

Traditionally defined as follows:
Revenue = Price * Quantity of products

Revenue is one of the components of a company’s income. In international practice, revenue is understood as the inflow or other increase in a company's assets or the settlement of its obligations that occurs as a result of the company’s core or main activity.^[1]

This is an important indicator for assessing the financial condition and efficiency of a company. It makes it possible to determine how successfully a company sells its products or services on the market. In addition, revenue can be used to calculate other financial indicators such as profit, profitability, and market share.

Various factors can influence this indicator, including demand for goods or services, market competition, economic conditions, and the company's marketing efforts. Therefore, its analysis and monitoring are important tasks for the successful development of a business.

Annual Revenue Alphatec Holdings

2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
612 M	482 M	351 M	243 M	145 M	113 M	91.7 M	102 M	120 M	185 M	207 M	205 M	196 M	198 M

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
612 M	91.7 M	232 M

Quarterly Revenue Alphatec Holdings

2025-Q2	2025-Q1	2024-Q4	2024-Q3	2024-Q2	2024-Q1	2023-Q4	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
186 M	169 M	-	151 M	146 M	138 M	-	118 M	117 M	109 M	-	89.8 M	84.2 M	70.9 M	-	62.9 M	62.2 M	44.1 M	-	41.2 M	29.6 M	30.1 M	-	29.2 M	27.3 M	24.6 M	-	23 M	22 M	21.3 M	-	23.1 M	24.4 M	28 M	27.1 M	26.7 M	32.2 M	34.2 M	34.8 M	31.7 M	46.6 M	48.6 M	53.6 M	51 M	53.2 M	49.2 M	53.1 M	50.2 M	51 M	50.4 M	52.7 M	46.8 M	48.2 M	48.5 M	49.5 M	47.6 M	50.9 M	49.7 M

All numbers in USD currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
186 M	21.3 M	59.2 M

References

Adhikari, B. (2010). Impact of Revenue Planning In Nepal Investment Bank Limited (Doctoral dissertation, Faculty of Management).

Revenue of other stocks in the Medical devices industry

Issuer	Revenue	Price	% 24h	Market Cap	Country
Acutus Medical AFIB	7.16 M	-	-26.83 %	$ 2.62 M	USA
Allied Healthcare Products AHPI	6.02 M	-	3.58 %	$ 2.21 M	USA
Abiomed ABMD	848 M	-	-	$ 17.2 B	USA
Cognyte Software Ltd. CGNT	443 M	$ 9.54	2.03 %	$ 685 M	Israel
AxoGen AXGN	187 M	$ 32.81	5.67 %	$ 1.45 B	USA
GenMark Diagnostics, Inc. GNMK	172 M	-	-	$ 1.77 B	USA
Axonics Modulation Technologies AXNX	274 M	-	-	$ 3.31 B	USA
Apyx Medical Corporation APYX	52.3 M	$ 3.47	-2.49 %	$ 120 M	USA
Obalon Therapeutics, Inc. OBLN	1.59 M	-	-5.86 %	$ 30.6 M	USA
EDAP TMS S.A. EDAP	44.1 M	$ 3.75	-0.79 %	$ 140 M	France
Bio-Rad Laboratories BIO	2.57 B	$ 323.35	-0.66 %	$ 9.12 B	USA
Apollo Endosurgery APEN	76.9 M	-	-	$ 475 M	USA
BioSig Technologies BSGM	40 K	-	37.08 %	$ 85.7 M	USA
Boston Scientific Corporation BSX	16.7 B	$ 98.56	0.8 %	$ 145 B	USA
Conformis CFMS	62 M	-	-	$ 16.4 M	USA
Bruker Corporation BRKR	3.37 B	$ 53.03	0.68 %	$ 7.9 K	USA
CONMED Corporation CNMD	1.31 B	$ 43.31	-0.39 %	$ 1.34 B	USA
Abbott Laboratories ABT	42 B	$ 126.93	-0.69 %	$ 221 B	USA
Cardiovascular Systems CSII	236 M	-	0.15 %	$ 844 M	USA
CryoLife, Inc. CRY	253 M	-	-4.14 %	$ 702 M	USA
Cutera CUTR	49.5 M	-	-10.19 %	$ 1.99 M	USA
InMode Ltd. INMD	358 M	$ 15.62	0.36 %	$ 1.24 B	Israel
Eargo EAR	37.2 M	-	-	$ 10.2 M	USA
Electromed ELMD	64 M	$ 29.03	2.25 %	$ 245 M	USA
Hancock Jaffe Laboratories, Inc. HJLI	4.25 K	-	-1.98 %	$ 98.3 M	USA
Itamar Medical Ltd. ITMR	41 M	-	0.03 %	$ 1.58 B	Israel
Misonix, Inc. MSON	62.5 M	-	-	$ 462 M	USA
Neovasc NVCN	2.55 M	-	-	$ 111 M	Canada
Second Sight Medical Products EYES	1 K	-	-0.97 %	$ 54.4 M	USA
Dynatronics Corporation DYNT	27.4 M	-	14.99 %	$ 929 K	USA
Intersect ENT, Inc. XENT	80.6 M	-	-	$ 955 M	USA
GBS GBS	3.05 M	-	-0.57 %	$ 7.12 M	USA
Align Technology ALGN	4 B	$ 166.78	-0.52 %	$ 12.5 B	USA
Accuray Incorporated ARAY	459 M	$ 0.88	-1.53 %	$ 90.4 M	USA
Avinger AVGR	7.65 M	-	-20.74 %	$ 369 K	USA
ClearPoint Neuro CLPT	31.4 M	$ 15.3	0.22 %	$ 414 M	USA
Profound Medical Corp. PROF	7.2 M	$ 8.18	5.82 %	$ 180 M	Canada
FONAR Corporation FONR	97.6 M	$ 18.55	0.03 %	$ 122 M	USA
Globus Medical GMED	2.52 B	$ 90.47	-3.03 %	$ 12.3 B	USA
IRIDEX Corporation IRIX	51.9 M	$ 1.19	0.85 %	$ 19.2 M	USA
Integra LifeSciences Holdings Corporation IART	1.61 B	$ 13.05	-0.61 %	$ 1 B	USA
IRadimed Corporation IRMD	73.2 M	$ 97.9	-0.17 %	$ 1.24 B	USA
Aziyo Biologics AZYO	24.7 M	-	1.37 %	$ 20.5 M	USA
OrthoPediatrics Corp. KIDS	205 M	$ 18.33	-2.19 %	$ 423 M	USA
Establishment Labs Holdings ESTA	166 M	$ 69.6	0.4 %	$ 1.96 B	Costa-rica
Invacare Corporation IVC	181 M	-	-	$ 24.7 M	USA